DEFA14A: Psychemedics Corporation Approves Plan to Terminate Registration and Delist from Nasdaq

Psychemedics Corporation plans to terminate the registration of its common stock and delist from the Nasdaq Capital Market to reduce costs and focus on long-term stockholder value.

Summary

• Psychemedics Corporation has entered into a stock purchase agreement with investors to sell up to 1,595,744 shares at $2.35 per share, totaling up to $3,750,000.
• The company intends to use the proceeds to purchase fractional shares resulting from a proposed reverse stock split and for working capital.
• The Board has approved a plan to cease registration of its common stock and delist from the Nasdaq Capital Market, contingent on stockholder approval at the 2024 Annual Meeting.
• The proposed reverse stock split will be at a ratio between 1-for-4,000 and 1-for-6,000, with stockholders owning fewer shares than the ratio denominator being cashed out at $2.35 per share.
• Continuing stockholders will undergo a forward stock split immediately after the reverse split, maintaining their original number of shares.
• The company estimates that approximately 1.2 million shares (21% of outstanding shares) will be cashed out at a cost of approximately $2.8 million, plus $700,000 in transaction expenses.
• Psychemedics anticipates annual savings exceeding $900,000 from deregistration and delisting.
• The transaction may be considered a 'going private' transaction.
• The Board may abandon the transaction and terminate the Purchase Agreement at any time prior to the filing and effectiveness of the applicable amendments to the Company's amended and restated certificate of incorporation, even after stockholder approval.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the company is delisting, it's doing so to reduce costs and improve long-term value. The cash-out price offers a premium to small shareholders, and the company secures additional working capital.

Positives

• The company expects to save over $900,000 annually by deregistering and delisting.
• Small stockholders will receive a premium of $2.35 per share for their fractional shares.
• Management will be able to focus more on core operations without the burden of public company costs.
• The transaction provides liquidity to smaller stockholders without brokerage commissions.

Negatives

• The company will cease to file annual, quarterly, current and other reports and documents with the SEC.
• Stockholders will cease to receive annual reports and proxy statements.
• The company's common stock will no longer be listed on the Nasdaq Capital Market.
• The transaction may be considered a 'going private' transaction.

Risks

• The transaction is subject to stockholder approval.
• The Board may abandon the transaction at any time.
• The company may not realize the anticipated cost savings.
• The company's stock may become less liquid after delisting.
• The company will no longer have access to the public markets for capital raising.

Future Outlook

Psychemedics intends to terminate the registration of its common stock and delist from the Nasdaq Capital Market, contingent on stockholder approval, to reduce costs and focus on long-term stockholder value. The company anticipates savings exceeding $900,000 annually as a result of the proposed deregistration and delisting transaction.

Management Comments

• The participating members of the Board determined unanimously that the proposed transaction is in the best interests of the Company and its stockholders.
• Without its public company status, Psychemedics would have an ongoing cost structure befitting its current and foreseeable scale of operations and its management would be able to have an increased focus on core operations.

Industry Context

This announcement reflects a trend among smaller public companies to consider 'going private' transactions to avoid the costs and regulatory burdens associated with maintaining public company status. This decision is often driven by a desire to streamline operations and focus on long-term growth without the scrutiny of quarterly reporting and the expenses of compliance.

Comparison to Industry Standards

• The decision to delist and deregister to save on compliance costs is a strategy employed by smaller companies that find the expenses of being public outweigh the benefits.
• Comparable companies that have taken similar actions often cite the same reasons: reduced administrative burden, increased management focus, and the ability to operate with a longer-term perspective without the pressure of quarterly earnings reports.
• The reverse stock split and cash-out of fractional shares are standard mechanisms used in going-private transactions to reduce the number of shareholders below the threshold requiring SEC registration.

Stakeholder Impact

• Shareholders owning fewer shares than the reverse stock split ratio denominator will be cashed out at $2.35 per share.
• Continuing shareholders will not be affected by the reverse stock split due to the subsequent forward stock split.
• Employees may benefit from a more focused management team and reduced operational costs.
• The company expects to enhance long-term stockholder value by reducing costs and focusing resources on core operations.

Next Steps

• File a preliminary proxy statement with the SEC.
• Convene the 2024 Annual Meeting of Stockholders to vote on the proposed transaction.
• Obtain stockholder approval for the stock split and purchase agreement.
• Terminate the registration of the common stock with the SEC and delist from the Nasdaq Capital Market.

Key Dates

Keywords

delisting, reverse stock split, deregistration, stock purchase agreement, going private, Psychemedics, Nasdaq